Evaluation of platelet activation in patients supported by the Jarvik 2000* high-rotational speed impeller ventricular assist device

Journal of Thoracic and Cardiovascular Surgery

Volumn 137, Issue 3, 2009, Pages 736-741

  Löffler, Christoph ^a   Straub, Andreas ^b   Bassler, Nicole ^b   Pernice, Katharina ^a   Beyersdorf, Friedhelm ^a   Bode, Christoph ^a   Siegenthaler, Michael P ^a   Peter, Karlheinz ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CD40 LIGAND; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HAPTOGLOBIN; LACTATE DEHYDROGENASE; PADGEM PROTEIN;

ADULT; AGED; ARTICLE; ASSISTED CIRCULATION; BLOOD COMPONENT; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; HEART ASSIST DEVICE; HEART FAILURE; HEMOLYSIS; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE RELEASE REACTION; THROMBOEMBOLISM;

AGED; BIOMECHANICS; EQUIPMENT DESIGN; HEART FAILURE; HEART-ASSIST DEVICES; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION;

EID: 60949094794     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2008.09.019     Document Type: Article

References (19)

1. Frazier O.H., Shah N.A., Myers T.J., Robertson K.D., Gregoric I.D., and Delgado R. Use of the Flowmaker (Jarvik 2000) left ventricular assist device for destination therapy and bridging to transplantation. Cardiology 101 (2004) 111-116
2. Westaby S., Banning A.P., Jarvik R., Frazier O.H., Pigott D.W., Jin X.Y., et al. First permanent implant of the Jarvik 2000 Heart. Lancet 356 (2000) 900-903
3. Raman J., and Jeevanadam V. Destination therapy with ventricular assist devices. Cardiology 101 (2004) 104-110
4. Haj-Yahia S., Birks E.J., Rogers P., Bowles C., Hipkins M., George R., et al. Midterm experience with the Jarvik 2000 axial flow left ventricular assist device. J Thorac Cardiovasc Surg 134 (2007) 199-203
5. Hathcock J.J. Flow effects on coagulation and thrombosis. Arterioscler Thromb Vasc Biol 26 (2006) 1729-1737
6. Costanzo M.R., Augustine S., Bourge R., Bristow M., O'Connell J.B., Driscoll D., et al. Selection and treatment of candidates for heart transplantation. A statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 92 (1995) 3593-3612
7. Siegenthaler M.P., Westaby S., Frazier O.H., Martin J., Banning A., Robson D., et al. Advanced heart failure: feasibility study of long-term continuous axial flow pump support. Eur Heart J 26 (2005) 1031-1038
8. Siegenthaler M.P., Martin J., van de Loo A., Doenst T., Bothe W., and Beyersdorf F. Implantation of the permanent Jarvik-2000 left ventricular assist device: a single-center experience. J Am Coll Cardiol 39 (2002) 1764-1772
9. Frazier O.H., Myuers T.J., Westaby S., and Gregoric I.D. Clinical experience with an implantable, intracardiac, continuous flow circulatory support device: physiologic implications and their relationship to patient selection. Ann Thorac Surg 77 (2004) 133-142
10. Siegenthaler M.P., Martin J., Frazier O.H., and Beyersdorf F. Implantation of the permanent Jarvik-2000 left-ventricular-assist-device: surgical technique. Eur J Cardiothorac Surg 21 (2002) 546-548
11. Siegenthaler M.P., Martin J., Gutwald R., Bahr R., Westaby S., Schmelzeisen R., et al. Anterior approach to implant the Jarvik 2000 with retroauricular power supply. Ann Thorac Surg 80 (2005) 745-747
12. Peter K., Kohler B., Straub A., Ruef J., Moser M., Nordt T., et al. Flow cytometric monitoring of glycoprotein IIb/IIIa blockade and platelet function in patients with acute myocardial infarction receiving reteplase, abciximab, and ticlopidine: continuous platelet inhibition by the combination of abciximab and ticlopidine. Circulation 102 (2000) 1490-1496
13. Delgado III R., Frazier O.H., Myers T.J., Gregoric I.D., Robertson K., Shah N.A., et al. Direct thrombolytic therapy for intraventricular thrombosis in patients with the Jarvik 2000 left ventricular assist device. J Heart Lung Transplant 24 (2005) 231-233
14. Peter K., Straub A., Kohler B., Volkmann M., Schwarz M., Kübler W., et al. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia. Am J Cardiol 84 (1999) 519-524
15. Bassler N., Loeffler C., Mangin P., Yuan Y., Schwarz M., Hagemeyer C.E., et al. A mechanistic model for paradoxical platelet activation by ligand-mimetic αIIb β3 (GPIIb/IIIa) antagonists. Arterioscler Thromb Vasc Biol 27 (2007) e9-e15
16. Gawaz M., Neumann F.J., and Schomig A. Evaluation of platelet membrane glycoproteins in coronary artery disease: consequences for diagnosis and therapy. Circulation 99 (1999) E1-E11
17. Anwaruddin S., Askari A., and Topol E. Redefining risk in acute coronary syndromes using molecular medicine. J Am Coll Cardiol 49 (2007) 279-289
18. Kilic A., Nolan T.D., Li T., Yankey G.K., Prastein D.J., Cheng G., et al. Early in vivo experience with the pediatric Jarvik 2000 heart. ASAIO J 53 (2007) 374-378
19. Aaronson K.D., Schwartz J.S., Chen T.M., Wong K.L., Goin J.E., and Mancini D.M. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 95 (1997) 2660-2667